From: Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants
Author, year | Trial name | Drug and dose | Initial regimen | N pts, overall | N pts ≥75 years (%) | N pts CrCl ≤50 ml/min (%) |
---|---|---|---|---|---|---|
Schulman, 2009 Schulman, 2014 | RE-COVER I-II | Dabigatran 150 mg bd | Heparin lead-in | 5107 | 259 (12) | 167 (5.2) |
Bauersachs, 2010 Buller, 2012 | EINSTEIN DVT-PE | Rivaroxaban 20 mg od | Rivaroxaban 15 mg bd for 3 weeks | 8281 | 1283 (18) | 664 (8.0) |
Agnelli, 2013 | AMPLIFY | Apixaban 5 mg bd | Apixaban 10 mg bd for 1 week | 5395 | 768 (14) | 327 (6.2) |
Buller, 2013 | HOKUSAI | Edoxaban 60 or 30* mg od | Heparin lead-in | 8292 | 1004 (12) | 541 (6.6) |